Saturday, July 11, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Clinical program

GSK Biologicals' GSK2340274A (two different formulations)

Phase 2 · mab · Influenza

GSK Biologicals' GSK2340274A (two different formulations) for Influenza is a Phase 2 program (mab) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Internal code 114495

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GlaxoSmithKline
Phase
Phase 2
Modality
mab
Indication
Influenza
Status
completed
Trials
1